FDA: Flexibility okay for gaps in gene therapy trials
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaRegulatory Intelligence/Policy